New drug ENX-104 tested in healthy volunteers for safety and brain activity
NCT ID NCT07253272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed early-phase study gave a single oral dose of ENX-104 to 10 healthy volunteers to check its safety, how the body processes it, and how well it binds to D2/D3 receptors in the brain. The main goal was to track any side effects. Since this was a small, first-in-human study in healthy people, it does not test whether the drug works for any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENX-104
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel London EPCU
London, Middlesex, HA1 3UJ, United Kingdom